A detailed history of Exodus Point Capital Management, LP transactions in Spring Works Therapeutics, Inc. stock. As of the latest transaction made, Exodus Point Capital Management, LP holds 114,300 shares of SWTX stock, worth $4.21 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
114,300
Previous 142,355 19.71%
Holding current value
$4.21 Million
Previous $5.36 Million 31.72%
% of portfolio
0.02%
Previous 0.04%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$32.04 - $42.76 $898,882 - $1.2 Million
-28,055 Reduced 19.71%
114,300 $3.66 Million
Q2 2024

Aug 13, 2024

BUY
$36.06 - $47.62 $3.93 Million - $5.19 Million
108,884 Added 325.31%
142,355 $5.36 Million
Q1 2024

May 14, 2024

BUY
$36.5 - $52.5 $235,388 - $338,572
6,449 Added 23.87%
33,471 $1.65 Million
Q3 2023

Nov 09, 2023

BUY
$23.12 - $31.38 $624,748 - $847,950
27,022 New
27,022 $625,000
Q3 2022

Nov 10, 2022

BUY
$24.1 - $39.66 $1.39 Million - $2.29 Million
57,652 Added 214.15%
84,573 $2.41 Million
Q2 2022

Aug 19, 2022

BUY
$18.36 - $60.07 $494,269 - $1.62 Million
26,921 New
26,921 $663,000
Q1 2021

May 17, 2021

SELL
$65.1 - $93.59 $236,573 - $340,106
-3,634 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$48.36 - $77.92 $175,740 - $283,161
3,634 New
3,634 $264,000
Q3 2020

Nov 16, 2020

SELL
$36.14 - $51.99 $298,769 - $429,801
-8,267 Closed
0 $0
Q2 2020

Aug 14, 2020

SELL
$22.98 - $48.57 $522,312 - $1.1 Million
-22,729 Reduced 73.33%
8,267 $347,000
Q1 2020

May 15, 2020

BUY
$20.44 - $41.21 $633,558 - $1.28 Million
30,996 New
30,996 $837,000

Others Institutions Holding SWTX

About SpringWorks Therapeutics, Inc.


  • Ticker SWTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,401,100
  • Market Cap $2.3B
  • Description
  • SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...
More about SWTX
Track This Portfolio

Track Exodus Point Capital Management, LP Portfolio

Follow Exodus Point Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Exodus Point Capital Management, LP with notifications on news.